Internal link ProQR Announces First Quarter 2023 Operating and Financial Results May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform December 22, 2022 at 11:15 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 November 14, 2022 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2022 Operating and Financial Results November 09, 2022 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference November 03, 2022 at 11:00 AM UTC
Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs August 11, 2022 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results August 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium June 28, 2022 at 11:00 AM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates June 01, 2022 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022 May 09, 2022 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2022 Operating and Financial Results May 05, 2022 at 08:30 PM UTC
Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 April 26, 2022 at 08:10 PM UTC
Internal link ProQR to Participate in the Kempen Life Sciences Conference April 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy April 13, 2022 at 11:00 AM UTC
Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit April 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit March 23, 2022 at 08:30 PM UTC
Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board March 07, 2022 at 12:00 PM UTC